Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion

Clinical Immunology

Volumn 104, Issue 1, 2002, Pages 14-20

  Hayashi, Takashi ^a   Tanaka, Hiroshi ^a   Tanaka, Junta ^a   Wang, Rongfu ^b   Averbook, Bruce J ^c   Cohen, Peter A ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Electrofusion; Immunotherapy; T cells; Tumor immunity; Vaccination

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; MACROGOL; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ELECTROFUSION (CELL); EMBRYO; HUMAN; HUMAN CELL; HYBRID CELL; IMMUNOGENICITY; LUNG TUMOR; MOUSE; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; SKIN TUMOR; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

EID: 0036334152     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2002.5224     Document Type: Article

References (26)

1. Dendritic cells and immune-based therapies
2. Dendritic cells and the control of immunity
3. Active immunization against cancer with dendritic cells: The near future
4. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
5. Reversal of tolerance to human MUC 1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
6. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity
7. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
8. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
9. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model
10. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
11. Electrofusion
12. Electrofusion of mammalian cells
13. Studies on the chemotherapy of experimental brain tumors: Development of an experimental model
14. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
15. The selection and characterization of an invasive variant of the B 16 melanoma
16. Kat: A high-efficiency retroviral transduction system for primary human T lymphocytes
17. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
18. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
19. + T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression
20. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity
21. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo
22. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma
23. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
24. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo
25. Therapeutic efficacy of OX-40R antibody depends on the tumor immunogenicity and anatomic site of tumor growth
26. Augmentation vs. Inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor